Ibogaine for Opioid Use Disorder: An Unrecognized Risk
Journal of Addiction Medicine – January 15, 2026
Source: OpenAlex
Summary
Ibogaine has sparked interest as a potential treatment for opioid use disorder (OUD), with several states investing heavily in its exploration. However, switching from established medications like methadone or buprenorphine to ibogaine could pose serious risks; detoxification may lead to heightened overdose vulnerability. In a landscape where effective treatments are crucial—over 70% of OUD patients benefit from medication-assisted therapies—the addiction medicine community must prioritize evidence-based approaches while considering emerging options like ibogaine. Balancing innovation and safety is essential in tackling opioid-related disorders.
Abstract
The psychedelic substance, ibogaine, has garnered growing interest among policymakers, researchers, and the public in its potential use for opioid use disorder (OUD). Many states are allocating significant funds to investigate it further. However, some proponents of ibogaine are framing it in opposition to (versus complementary to) standard, mortality-reducing medications for OUD (MOUD). Although the path to OUD remission and recovery varies greatly among individuals, the stakes are high: "detoxification" from methadone or buprenorphine in favor of an as-yet unproven therapy like ibogaine could result in an increased risk of opioid overdose for some. The addiction medicine community should be aware of this potential risk and defend evidence-based care, even as treatments like ibogaine are developed for OUD.